A Multicentre, Dose Finding, Phase II Study of CP-4055 in Combination With Sorafenib in Patients With Metastatic Malignant Melanoma.

Trial Profile

A Multicentre, Dose Finding, Phase II Study of CP-4055 in Combination With Sorafenib in Patients With Metastatic Malignant Melanoma.

Suspended
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2012

At a glance

  • Drugs Elacytarabine; Sorafenib
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Jul 2008 Status changed from recruiting to suspended, according to a Clavis media release. The drug's safety profile was good under the current dosing regimen, but clinical activity was modest and only a limited number patients showed disease stabilisation.
    • 23 Apr 2008 The trial is progressing according to plan, according to a Clavis Pharma media release.
    • 13 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top